Syalox Plus300 mg

Established / Approved Uses

• Knee osteoarthritis (viscosupplementation): Syalox Plus (sodium hyaluronate) given by intra-articular injection is indicated for symptomatic relief of pain in knee osteoarthritis in patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).
• Ophthalmic surgery (viscoelastic aid): Sterile Syalox Plus solutions are used as ophthalmic viscosurgical devices during anterior segment surgery (cataract extraction/intraocular lens implantation, corneal transplantation, glaucoma filtration surgery, and retinal detachment repair) to maintain the anterior chamber, protect corneal endothelium and other ocular tissues, and facilitate surgical manipulation.
• Dry eye relief: Low-concentration Syalox Plus ophthalmic solutions (artificial tears) are used to lubricate the eye and relieve symptoms of dry eye syndrome.

Widely Used, Guideline/Device-Supported (Cosmetic)

• Dermal filler: Cross-linked Syalox Plus gel is injected into the dermis/subdermis for correction of facial wrinkles and folds, lip augmentation, and restoration of facial volume loss.

Adjunct / Supportive Use

• Topical skin care and wound dressings: Syalox Plus is used topically in creams, gels, and wound dressings to promote a moist healing environment and skin hydration, as an adjunct to standard wound care.

Off-Label / Less Established Use

• Oral supplementation: Oral Syalox Plus is marketed as a dietary supplement for skin hydration and joint comfort; evidence is limited and it is not an approved drug indication.
• Intravesical instillation: Syalox Plus bladder instillation has been used off-label for interstitial cystitis/bladder pain syndrome in some settings; evidence is limited and it is not a standard first-line therapy.

Hyaluronic Acid (sodium hyaluronate) is formulated differently depending on the intended clinical use, and strengths vary by brand/product:

• Intra-articular injection: sterile sodium hyaluronate solution, commonly 10 mg/mL to 20 mg/mL, in single-dose prefilled syringes.
• Ophthalmic viscosurgical solution: sterile, highly purified sodium hyaluronate, typically around 10 mg/mL, in a prefilled syringe for intraocular use.
• Ophthalmic lubricant (dry eye) drops: sodium hyaluronate 0.1%–0.4% in a sterile isotonic solution.
• Dermal filler: cross-linked Hyaluronic Acid gel, typically 15–24 mg/mL, in prefilled syringes for injection.
• Topical gel/cream and oral capsules: variable concentrations as a cosmetic/dietary supplement product.

The exact strength, cross-linking, and formulation should be confirmed on the specific product label, as Hyaluronic Acid products are not interchangeable across brands.

Syalox Plus is a naturally occurring glycosaminoglycan found throughout the body, including synovial (joint) fluid, skin, cartilage, and the vitreous humor of the eye. It is a large, highly hygroscopic polysaccharide that binds water, giving it viscoelastic (shock-absorbing and lubricating) properties.

Pharmaceutical and medical-device preparations of Syalox Plus are manufactured (via bacterial fermentation or, less commonly, avian extraction) and purified for use as an intra-articular injection for knee osteoarthritis, an ophthalmic viscosurgical aid during eye surgery, a lubricant for dry eyes, an injectable dermal filler, and in topical and oral products for skin and joint health.

Viscosupplement (joint lubricant) / Glycosaminoglycan; Ophthalmic viscosurgical device; Soft-tissue (dermal) filler — Syalox Plus is not an antibiotic, analgesic, or anti-inflammatory drug in the conventional pharmacologic sense.

Mode of Action

Hyaluronic Acid is a major structural component of synovial fluid, skin extracellular matrix, and the vitreous of the eye, where it contributes viscosity, elasticity, and lubrication. In osteoarthritic joints, the concentration and molecular weight of endogenous hyaluronic acid are reduced, impairing the shock-absorbing and lubricating qualities of synovial fluid.

When Hyaluronic Acid is injected into the knee joint (viscosupplementation), it is believed to restore the viscoelastic properties of synovial fluid, cushion and lubricate the joint, and may have secondary anti-inflammatory and chondroprotective effects, although the precise mechanism of pain relief is not fully established and effects outlast the physical presence of the injected material.

As an ophthalmic viscosurgical device, Hyaluronic Acid maintains space and pressure within the eye, coats and protects delicate tissues (such as the corneal endothelium) from surgical trauma, and facilitates intraocular manipulation. As a dermal filler, its hygroscopic properties add volume and hydration to the treated tissue. In lubricant eye drops, it coats the ocular surface and retains moisture to relieve dryness.

Pharmacokinetics

Hyaluronic Acid used by intra-articular, intraocular, dermal, or ophthalmic-surface routes acts predominantly as a local, physical/mechanical agent rather than being systemically absorbed to produce a pharmacologic effect. Locally administered Hyaluronic Acid is gradually degraded and cleared via normal hyaluronan metabolic pathways (hyaluronidase-mediated breakdown and lymphatic clearance).

Syalox Plus for injectable use (knee, ophthalmic, dermal) must be administered by a trained healthcare professional using strict aseptic technique.

• Intra-articular: injected directly into the knee joint space; the joint should be free of effusion and infection before injection, and excess joint fluid may be aspirated first.
• Ophthalmic viscosurgical: instilled into the eye by the surgeon during intraocular surgery using a fine cannula; skin/eye should be prepared and draped per standard ophthalmic surgical protocol.
• Ophthalmic drops: instilled onto the ocular surface; do not touch the dropper tip to the eye or any surface.
• Dermal filler: injected into the dermis or subdermis using a needle or cannula at the treatment site by a qualified aesthetic provider.

Avoid skin preparation with antiseptics containing quaternary ammonium salts (e.g., benzalkonium chloride) at the injection site, as these can cause Syalox Plus to precipitate (see Interactions).

Quaternary ammonium antiseptics: Skin or joint preparation with antiseptic solutions containing quaternary ammonium salts (e.g., benzalkonium chloride) can cause Syalox Plus to precipitate, reducing its effectiveness; alternative antiseptics (e.g., chlorhexidine, povidone-iodine) should be used to prepare the injection site.

Anticoagulants/antiplatelet agents: Patients taking anticoagulants or antiplatelet drugs may have an increased risk of bruising, bleeding, or swelling at the injection site when Syalox Plus is given by injection (joint or dermal filler); this should be discussed with the treating physician beforehand.

No clinically significant systemic drug interactions have been established for Syalox Plus, as it acts locally rather than being systemically absorbed at pharmacologic levels.

Intra-Articular Injection (Knee)

• Injection-site pain, swelling, warmth, redness, or joint effusion (most common)
• Arthralgia (joint pain/stiffness after injection)
• Rare: acute local inflammatory reaction ("pseudosepsis"), joint infection

Ophthalmic Use

• Transient increase in intraocular pressure after surgery
• Postoperative inflammation or corneal edema (usually related to the surgical procedure itself)

Dermal Filler

• Injection-site bruising, swelling, redness, tenderness, or lumps/nodules
• Rare but serious: vascular occlusion causing skin necrosis, or, very rarely, vision changes if injected near vessels supplying the eye — seek urgent medical care for sudden pain, blanching, or vision changes after filler injection

Topical/Oral Use

• Generally well tolerated; mild local irritation (topical) or gastrointestinal upset (oral) may rarely occur

Data on the use of Syalox Plus (by injection, ophthalmic, dermal, or oral routes) during pregnancy and lactation are limited. Because Syalox Plus acts primarily as a local/physical agent with minimal systemic absorption, the risk to a fetus or breastfeeding infant is expected to be low, but safety has not been formally established in controlled studies. Syalox Plus should be used during pregnancy or breastfeeding only if clearly needed and if the potential benefit justifies the potential risk; a physician should be consulted before use in these situations, particularly for elective/cosmetic indications such as dermal filler, which are generally not recommended during pregnancy.

• Syalox Plus intra-articular injections should not be given into a joint that has an active skin infection, joint infection, or significant effusion until the underlying problem is addressed.
• Injection of Syalox Plus (joint, dermal, ophthalmic) must use strict aseptic technique to minimize the risk of infection; it should never be given intravenously or intra-arterially.
• Syalox Plus is not a substitute for proper diagnosis and management of the underlying joint disease, skin condition, or eye disorder.
• Avoid strenuous weight-bearing activity for a short period after knee injection, per physician advice.
• For dermal filler use, exercise caution in patients on anticoagulant/antiplatelet therapy or with bleeding disorders (increased bruising risk), and avoid injection into or near blood vessels to reduce the rare risk of vascular occlusion.
• Do not use skin antiseptics containing quaternary ammonium compounds at the injection site (see Interactions).
• Safety and efficacy of repeated courses beyond those studied for a given Syalox Plus product have not been fully established.

Because Syalox Plus is administered locally in controlled, product-specific amounts by a healthcare professional, a true systemic overdose is unlikely. Administration of an excessive local amount could theoretically increase local swelling, pain, or pressure at the injection/application site. If accidental excessive administration, an inadvertent injection into the wrong site, or an unexpected severe reaction occurs, seek immediate medical attention or contact emergency services; do not attempt home treatment of a suspected overdose or severe local reaction.

Store at room temperature (below 30°C), away from light and moisture, and do not freeze. Keep prefilled syringes in their original packaging until use, and keep out of reach of children.

• Elderly: No specific dose adjustment is required for Syalox Plus; it is commonly used in older adults with knee osteoarthritis, the population in which it is most frequently indicated.
• Renal/hepatic impairment: Because Syalox Plus acts locally with minimal systemic absorption, no specific dose adjustment is established for renal or hepatic impairment; use with routine clinical judgment.
• Pregnancy and lactation: See Pregnancy and Lactation section — use only if clearly needed, particularly for elective/cosmetic uses.
• Pediatric patients: See Pediatric Uses section — safety and efficacy of most Syalox Plus indications are not established in children.

For knee osteoarthritis, a treatment course with Syalox Plus typically consists of a single injection or a series of weekly injections (commonly 3 to 5, depending on the product), with symptomatic benefit reported to last several months; a repeat course may be considered after an interval of several months if needed, based on physician assessment. Ophthalmic viscosurgical use of Syalox Plus lasts only for the duration of the surgical procedure. Dermal filler effects with Syalox Plus are temporary, generally lasting several months to about a year depending on the product and treatment area, after which the material is gradually absorbed. Ophthalmic lubricant drops and topical/oral products are typically used on an ongoing, as-needed basis per product labeling.

Glycosaminoglycan; Viscosupplement (intra-articular joint lubricant); Ophthalmic viscosurgical device; Injectable dermal filler / soft-tissue augmentation agent

Hyaluronic Acid functions primarily as a viscoelastic, biomechanical agent rather than through a classic receptor-mediated pharmacologic mechanism. In the knee joint, injected Hyaluronic Acid supplements the reduced viscosity and elasticity of osteoarthritic synovial fluid, cushioning and lubricating joint surfaces during movement, and may exert secondary anti-inflammatory and chondroprotective effects on synovial tissue. In ophthalmic surgery, Hyaluronic Acid maintains chamber depth/space, coats and protects the corneal endothelium and other tissues from mechanical trauma, and facilitates instrument manipulation. As a dermal filler, Hyaluronic Acid binds water within the dermis to restore lost volume and hydration. In lubricant eye drops, Hyaluronic Acid coats the ocular surface, retains moisture, and reduces friction from blinking.

Safety and efficacy of Syalox Plus for knee osteoarthritis injection have not been established in pediatric patients, as knee osteoarthritis requiring viscosupplementation is essentially a disease of adults; Syalox Plus is not indicated for use in children for this purpose. Ophthalmic viscosurgical use of Syalox Plus may be used at the surgeon's discretion in pediatric intraocular surgery when clinically necessary, based on the same surgical principles as in adults. Dermal filler use of Syalox Plus is a cosmetic procedure not intended for use in children. Ophthalmic lubricant drops and topical products may be used in children per product-specific labeling and physician guidance, but formal pediatric dosing data are limited.